Leaders in Pharmaceutical Business Intelligence (LPBI) Group

March 19, 2014

5PM

Public & Private Partnerships

Co-Chaired by: Louis J. DeGennaro, Interim President and CEO, Chief Mission Ocer, The Leukemia and Lymphoma Society
Beth Jacobs, Managing Partner, Excellentia Global Partners
Featuring: Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
Dov Hass, Associate, Morgan, Lewis & Bockius LLP
Kristina Khodova, Head of Oncology Projects, Biomed Cluster, Skolkovo Foundation
Louise M. Perkins, Chief Science Ocer, Melanoma Research Alliance
Peter L. Hoang, Managing Director, Oce of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
Steven Young, President & COO, Addario Lung Cancer Medical Institute
Walter M. Capone, President, Multiple Myeloma Research Foundation

Public & Private Partnership

• Foundation are playing a new role: The enable Cancer Research, links to biopharma, Scientific staff, understanding of the commercial landscape
• Universities: Public & Private

Question #1: Difficulties in working with small biotech companies

Non-Profits are disease focus, Biotech have expectation to gain capital funding from the Non-Profits

Non-Profit has access to Patients information and disease condition in the pre-approval period, Consortia: addresses access to Resources do not invest or fund pharma companies, they fund diagnostics lab, stem cell companies

Foundations  have right to publish data, IP ownership is still unresolved an issue, Dana Farber can’t be encouraged to give away its IP but a Foundation can accelerate the process.

IP Licensing

Academic institution as LISENSORS WHILE HAVING having bond obligation, Tax exempt status is exclusive, while the bond owner status is non-exclusive

Appetite for Risk – Venture Capital vs Foundation

• Louis J. DeGennaro, Interim President and CEO, Chief Mission Ocer, The Leukemia and Lymphoma Society – provides $60 millions a year for R&D – they do take significant Risk. Size of population of patients is not a factor, serving all is. No detection, No screening, Patients present with full blown disease
• Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance — Risk does not belong to this organization. Foundation funded research on the disparity between Black and White patients.
• Louise M. Perkins, Chief Science Officer, Melanoma Research Alliance – UV cause, funding research for personalized. medicine. Foundation has educated FDA, Sequencing of melanoma larger that sequencing of the Genome
• Steven Young, President & COO, Addario Lung Cancer Medical Institute 70% of Lung Cancer Patients were not Smokers

__________________

8:00 AM – On the 40th Floor of 7 World Trade Center in NYC

@  The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Follow me @pharma_BI

• Event Coverage
• Cancer & Genomic – Volume One in LPBI’s BioMed e-Series C: Cancer
• Alnion Venture Funding Prospecting & Negotiation

Aviva Lev-Ari, PhD, RN

Founder and Director

Leaders in Pharmaceutical Business Intelligence

Editor-in-Chief

http://pharmaceuticalintelligence.com